These findings point to a level of dysregulation among melanoma patient circulating B cells, evident through expanded populations of TGF-β+, PD-L1+ Breg, and reduced IFN-γ+, TNF-α+ pro-inflammatory B cell compartments in the total peripheral blood B cell populations of patients with melanoma. This evidence concerns the gene TNF and melanoma.